CR1 and inflammatory bowel disease: Since we mentioned earlier that increased MBL expression in IBD patients can affect the inflammatory response via the lectin pathway (Bąk-Romaniszyn et al., 2020), our results further support the therapeutical potential of targeting MBL–CR1 binding in UC patients.